stocks logo

WGS

GeneDx Holdings Corp
$
79.830
-1.62(-1.989%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
82.960
Open
81.390
VWAP
80.73
Vol
663.83K
Mkt Cap
2.28B
Low
79.390
Amount
53.59M
EV/EBITDA(TTM)
144.00
Total Shares
26.15M
EV
2.17B
EV/OCF(TTM)
--
P/S(TTM)
6.63
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
103.37M
+8.08%
0.442
-30.43%
93.71M
+21.9%
0.264
+508.86%
85.58M
+21.37%
0.106
-203.01%
Estimates Revision
The market is revising No Change the revenue expectations for GeneDx Holdings Corp. (WGS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -29.03%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-29.03%
In Past 3 Month
6 Analyst Rating
up Image
24.64% Upside
Wall Street analysts forecast WGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is 99.50 USD with a low forecast of 78.00 USD and a high forecast of 115.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
up Image
24.64% Upside
Current: 79.830
sliders
Low
78.00
Averages
99.50
High
115.00
Piper Sandler
Overweight
initiated
$110
2025-07-09
Reason
Piper Sandler initiated coverage of GeneDx with an Overweight rating and $110 price target. The firm views the company as a "fast grower in the under-penetrated" rare disease testing market. GeneDx has a "unique first-mover advantage" in rare disease testing and is at the beginning of profitability, the analyst tells investors in a research note. Piper sees a compelling entry point at current share levels.
Guggenheim
Subbu Nambi
maintain
$88 -> $115
2025-06-30
Reason
Guggenheim analyst Subbu Nambi raised the firm's price target on GeneDx to $115 from $88 and keeps a Buy rating on the shares. The price target increase reflects the tailwind and upside associated with the American Academy of Pediatrics guideline update, the analyst tells investors in a research note.
Craig-Hallum
Bill Bonello
Buy
maintain
$114
2025-06-24
Reason
Craig-Hallum analyst Bill Bonello recommends buying shares of GeneDx, even after the 19% jump on the American Academy of Pediatrics news on Monday afternoon, the analyst tells investors in a research note. The firm, which has a Buy rating and $114 price target on the shares, expects exome and genome testing to become the standard of care for pediatric rare diseases over time, and says the AAP guidance is another reason to believe.
Guggenheim
NULL -> Buy
initiated
$88
2025-05-15
Reason
Guggenheim initiated coverage of GeneDx with a Buy rating and $88 price target.
Guggenheim
Buy
initiated
$88
2025-05-15
Reason
Jefferies
Tycho Peterson
Hold
to
Buy
upgrade
$80
2025-05-09
Reason

Valuation Metrics

The current forward P/E ratio for GeneDx Holdings Corp (WGS.O) is 67.57, compared to its 5-year average forward P/E of 8.06. For a more detailed relative valuation and DCF analysis to assess GeneDx Holdings Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
8.06
Current PE
67.57
Overvalued PE
65.40
Undervalued PE
-49.28

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-110.11
Current EV/EBITDA
47.30
Overvalued EV/EBITDA
304.67
Undervalued EV/EBITDA
-524.88

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.79
Current PS
6.11
Overvalued PS
58.62
Undervalued PS
-23.04

Financials

Annual
Quarterly
FY2025Q1
YoY :
+39.56%
87.12M
Total Revenue
FY2025Q1
YoY :
-66.68%
-4.55M
Operating Profit
FY2025Q1
YoY :
-67.74%
-6.53M
Net Income after Tax
FY2025Q1
YoY :
-70.51%
-0.23
EPS - Diluted
FY2025Q1
YoY :
-124.04%
4.05M
Free Cash Flow
FY2025Q1
YoY :
+12.01%
67.13
Gross Profit Margin - %
FY2025Q1
YoY :
-94.01%
-3.96
FCF Margin - %
FY2025Q1
YoY :
-76.90%
-7.49
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.0M
USD
8
3-6
Months
13.1M
USD
13
6-9
Months
29.9M
USD
19
0-12
Months
73.4M
USD
13
Bought
0-3
2
8.6M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
2
604.1K
Volume
Months
3-6
2
479.0K
Volume
Months
6-9
5
916.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

WGS News & Events

Events Timeline

2025-06-25 (ET)
2025-06-25
09:04:55
GeneDx announces SeqFirst study data on rapid genomic testing in pediatrics
select
2025-06-24 (ET)
2025-06-24
07:48:07
GeneDx says AAP recommends exome, genome sequencing as tests for children
select
2025-06-23 (ET)
2025-06-23
09:20:12
Galatea Bio, Fabric Genomics partner on genetic testing for common diseases
select
Sign Up For More Events

News

7.0
07-23Globenewswire
Bragar Eagel & Squire, P.C Continues Investigations on Behalf of Lineage, Proficient Auto, PetMed, and GeneDx and Encourages Investors to Contact the Firm
3.0
07-22NASDAQ.COM
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
7.0
07-22Newsfilter
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Investigation With the DJS Law Group
Sign Up For More News

FAQ

arrow icon

What is GeneDx Holdings Corp (WGS) stock price today?

The current price of WGS is 79.83 USD — it has decreased -1.99 % in the last trading day.

arrow icon

What is GeneDx Holdings Corp (WGS)'s business?

arrow icon

What is the price predicton of WGS Stock?

arrow icon

What is GeneDx Holdings Corp (WGS)'s revenue for the last quarter?

arrow icon

What is GeneDx Holdings Corp (WGS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for GeneDx Holdings Corp (WGS)'s fundamentals?

arrow icon

How many employees does GeneDx Holdings Corp (WGS). have?

arrow icon

What is GeneDx Holdings Corp (WGS) market cap?